For Research Use Only. All content is intended for scientific reference only and does not constitute medical advice.

NAD+ (Nicotinamide Adenine Dinucleotide) is a coenzyme present in every living cell. It converts nutrients into ATP, the molecule cells use for energy, and activates sirtuins, a family of proteins that regulate DNA repair and metabolic signalling. These two functions alone make it one of the most researched molecules in cellular biology today.

NAD+ levels decline with age. Studies estimate a 30 to 50 percent drop across different tissues over time. As levels fall, sirtuin activity slows, DNA repair becomes less efficient, and cellular senescence accelerates. PARP enzymes compete for the remaining NAD+ during repair processes while chronic inflammation depletes it further. This compounding deficit is a central focus of current ageing biology research.

The mitochondria sit at the heart of NAD+ function. Research in mice showed that replenishing NAD+ via precursor supplementation protected against muscle and stem cell degeneration and extended lifespan in treated animals. A November 2025 study in Science Advances found that mitochondria actively maintain a large NAD+ reservoir, positioning them not just as energy producers but as active defenders of cellular NAD+ availability.

Because NAD+ cannot be directly absorbed by most cells, researchers study it through precursor molecules. The three most studied are NMN, NR, and nicotinamide. A January 2026 head-to-head trial published in Nature Metabolism compared all three in 65 healthy adults. NMN and NR both approximately doubled circulating NAD+ levels after 14 days. Nicotinamide produced only a brief transient effect at four hours. At comparable doses, NMN and NR performed similarly. The study also found both compounds modulate gut bacteria to increase short-chain fatty acids, linked to reduced systemic inflammation. Peptide Plus supplies independently tested NAD+ in both vial and pen format for use in research protocols.

The gaps in the research are worth being honest about. Raising NAD+ in blood does not confirm the same increase across all tissues. Some studies show elevated NAD+ in brain and muscle following precursor use. Others have not replicated this. A 2021 study found that high-dose NR in a cardiac model actually inhibited sirtuin activity due to nicotinamide accumulation as a conversion byproduct. More is not always better in biochemistry. Long-term safety data in research models remains limited, with most trials running weeks rather than years.

NAD+ has one of the strongest preclinical profiles in cellular biology. The evidence that precursor supplementation raises circulating NAD+ is solid and growing. What remains under active investigation is whether that translates to meaningful, measurable functional improvements across different tissue types and what the optimal forms and doses are for specific research contexts.

References

Zhu J et al. Restor Neurol Neurosci. 2021. PMID: 33450021
Zhang H et al. Science. 2016. PMID: 27127236
Christen S et al. Nature Metabolism. 2026. PMID: 41540253
Yang X et al. Food Frontiers. 2025. DOI: 10.1002/fft2.511
Science Advances. November 2025. DOI: 10.1126/sciadv.aea7460